<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1725">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05138705</url>
  </required_header>
  <id_info>
    <org_study_id>2021S00207-01</org_study_id>
    <nct_id>NCT05138705</nct_id>
  </id_info>
  <brief_title>Clinical Trial of Quadrivalent Influenza Virus Split Vaccine in Population Aged 3-8 Years</brief_title>
  <official_title>An Open Phase IV Clinical Trial of Quadrivalent Influenza Virus Split Vaccine to Evaluate the Safety and Immunogenicity in Healthy Population Aged 3-8 Years</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Institute Of Biological Products</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Institute Of Biological Products</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and immunogenicity of quadrivalent influenza virus split vaccine in&#xD;
      healthy population aged 3-8 years following different immunization procedures.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To evaluate the safety and immunogenicity of quadrivalent influenza virus split vaccine in&#xD;
      healthy population aged 3-8 years following different immunization procedures, and the&#xD;
      participants randomized to receive two injections of 0.5 mL quadrivalent influenza vaccine at&#xD;
      day 0 and 28.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 13, 2021</start_date>
  <completion_date type="Anticipated">December 13, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Subjects in one group received a first and a second dose of the vaccine at different time points.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Open Label</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>seroconversion rate of hemagglutination inhibition (HI) antibodies</measure>
    <time_frame>up to 56 days</time_frame>
    <description>28 days after receiving one and two doses of vaccine in subjects aged 3-8 years, respectively. Seroconversion rate of HI antibodies against any subtype of influenza virus in each group.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>seroprotection rate of HI antibodies</measure>
    <time_frame>up to 56 days</time_frame>
    <description>28 days after receiving one and two doses of vaccine in subjects aged 3-8 years, respectively. Seroprotection rate of HI antibodies against any subtype of influenza virus in each group.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>geometric mean increase (GMI) of HI antibodies</measure>
    <time_frame>up to 56 days</time_frame>
    <description>28 days after receiving one and two doses of vaccine in subjects aged 3-8 years, respectively. GMI of HI antibodies against any subtype of influenza virus in each group.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The proportion of all adverse reactions/events</measure>
    <time_frame>up to 56 days</time_frame>
    <description>The proportion of all adverse reactions/events in subjects through 28 days after the second dose.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>p value of difference of seroconversion rate in subjects with different immunization procedures</measure>
    <time_frame>up to 56 days</time_frame>
    <description>p value of the difference of seroconversion rate of HI antibodies at 28 days between subjects receiving one dose of vaccine and subjects receiving two.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>p value of difference of seroprotection rate in subjects with different immunization procedures</measure>
    <time_frame>up to 56 days</time_frame>
    <description>p value of the difference of seroprotection rate of HI antibodies at 28 days between subjects receiving one dose of vaccine and subjects receiving two.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>p value of difference of GMI in subjects with different immunization procedures</measure>
    <time_frame>up to 56 days</time_frame>
    <description>p value of the difference of GMI of HI antibodies at 28 days between subjects receiving one dose of vaccine and subjects receiving two.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reactogenicity Events</measure>
    <time_frame>208 days</time_frame>
    <description>The proportion of all adverse reactions/events in subjects from the day subjects receiving the first dose of vaccine to 180 days after subjects receiving the second dose.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">380</enrollment>
  <condition>Influenza, Human</condition>
  <arm_group>
    <arm_group_label>Outcome</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Quadrivalent influenza vaccine Participants randomized to receive two injections of 0.5 mL quadrivalent influenza vaccine at Day 0 and 28.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Quadrivalent Influenza Virus Split Vaccine</intervention_name>
    <description>0.5ml Quadrivalent influenza vaccine The inactivated split virion vaccines contained 15 μg of each hemagglutinin antigen of influenza A/H1N1, A/ H3N2, B/Victoria and B/Yamagata strains</description>
    <arm_group_label>Outcome</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy children aged 3-8 years. Volunteers are required to show vaccination&#xD;
             certificate if they have not received a previous flu vaccine.&#xD;
&#xD;
          -  Volunteers' legal guardian or client informed consent, voluntarily participate in and&#xD;
             sign informed consent. (Volunteers over the age of 8 also need informed consent and&#xD;
             signature)&#xD;
&#xD;
          -  Volunteers' legal guardian or client has the ability (non-illiterate) to understand&#xD;
             the study procedures, to use a thermometer, scale, and fill in a diary card as&#xD;
             required, and be able to complete the clinical study in compliance with the clinical&#xD;
             trial protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The axillary temperature greater than 37.0℃ on the day of enrollment;&#xD;
&#xD;
          -  Have suffered from influenza within previous 3 months or suffering currently&#xD;
             (confirmed by either clinical, serological or microbiological methods);&#xD;
&#xD;
          -  Have received any influenza vaccine (registered or experimental) within 6 months or be&#xD;
             going to receive other influenza vaccine during the study period;&#xD;
&#xD;
          -  Allergic to any component of the vaccine, or have a history of allergic reactions to&#xD;
             gentamicin sulfate;&#xD;
&#xD;
          -  A history of severe allergy to any vaccine or drug, or with a history of nervous&#xD;
             system damage;&#xD;
&#xD;
          -  Congenital malformations or developmental disorders, genetic defects, severe&#xD;
             malnutrition, etc;&#xD;
&#xD;
          -  Acute illness, severe chronic illness or acute attack of chronic disease on the day of&#xD;
             vaccination;&#xD;
&#xD;
          -  A history of live attenuated vaccination within 14 days prior to vaccination and a&#xD;
             history of other vaccinations within 7 days prior to vaccination;&#xD;
&#xD;
          -  Received immunoenhancement or inhibitor therapy within 3 months (continued oral or&#xD;
             intravenous administration for more than 14 days);&#xD;
&#xD;
          -  Congenital or acquired immune deficiency, HIV infection, lymphoma, leukemia or other&#xD;
             autoimmune diseases;&#xD;
&#xD;
          -  Have a history of asthma, the condition has been unstable for past two years and&#xD;
             require treatment, such as emergency treatment, hospitalization, intubation or oral or&#xD;
             intravenous administration of corticosteroids and so on;&#xD;
&#xD;
          -  Have received blood or blood-related products;&#xD;
&#xD;
          -  A history of convulsion, epilepsy, encephalopathy, guillain-barre syndrome, a history&#xD;
             of mental illness or have a mental illness family history;&#xD;
&#xD;
          -  A history of abnormal coagulation function (such as coagulation factor deficiency,&#xD;
             coagulation disease);&#xD;
&#xD;
          -  Planning to relocate before the end of the study or to leave for an extended period&#xD;
             during the scheduled study visit;&#xD;
&#xD;
          -  Participating in or planning to participate in other clinical trials in the near&#xD;
             future;&#xD;
&#xD;
          -  Any conditions judged by investigators that were inappropriate for participation in&#xD;
             this clinical trial.&#xD;
&#xD;
        Receiving the second dose of vaccine&#xD;
&#xD;
          -  Have a severe allergic reaction after receiving the first dose of vaccine;&#xD;
&#xD;
          -  Serious adverse events occurred that were causally related to the first dose of&#xD;
             vaccine injection；&#xD;
&#xD;
          -  After receiving the first dose of vaccine, the researchers will decide whether the&#xD;
             volunteer should participate in the study continued or not if the newly discovered&#xD;
             feature or newly condition occurred on volunteer that do not meet the inclusion&#xD;
             criteria or meet the exclusion criteria;&#xD;
&#xD;
          -  Other reasons for exclusion considered by the investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>8 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Li Zhang</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shandong Provincial Center for Disease Control and Prevention</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wenqing Chai</last_name>
    <phone>86-021-62750096</phone>
    <email>chaiwenqing@sinopharm.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dandan Chen</last_name>
    <phone>86-021-62750096</phone>
    <email>chendandan3@sinopharm.com</email>
  </overall_contact_backup>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 28, 2021</study_first_submitted>
  <study_first_submitted_qc>November 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 1, 2021</study_first_posted>
  <last_update_submitted>November 30, 2021</last_update_submitted>
  <last_update_submitted_qc>November 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>QIV, safety, immunogenicity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

